Helixmith Co.
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
07794 Korea, San Diego, California, Unit...Phone Number
(858) 922-2045Website
www.helixmith.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Helixmith Co.
Helixmith is a clinical-stage gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to address previously untreated diseases, and is listed on the KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), the most advanced pipeline candidate, is a plasmid DNA therapy being studied for painful diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis, coronary artery disease, and Charcot-Marie-Tooth disease.Explore more
Helixmith Co. Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Helixmith Co. your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Helixmith Co. has new funding data
Click to see if Helixmith Co. had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Helixmith Co., which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Helixmith Co. is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Helixmith Co.
Product Launch: Get notified when Helixmith Co. launches new products
Earning: See what the market has to say on Helixmith Co. recently announced quarterly report
Check if Helixmith Co. has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Helixmith Co. as Masked Content
Find more new buyers
Compare Similar Companies to Helixmith Co.
Compare insights from companies similar to Helixmith Co., focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Helixmith Co. is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Helixmith Co. is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Helixmith Co..
Helixmith Co. Tech Stack
A closer look at the technologies used by Helixmith Co.
See more technologies
Helixmith Co. News & Media
Helixmith to Present New ALS-Focused Development Program at Upcoming Conferences
LA JOLLA, Calif., Oct. 4, 2022 /PRNewswire/ -- Helixmith announced today that their CEO, Dr. Sunyoung Kim, will be presenting an overview of their ALS-focused program, named DART, Defeating ALS through Regenerative Therapeutics, at both the 2022 Cell & Gene Meeting on the Mesa and the...Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis)
LA JOLLA, Calif., Sept. 6, 2022 /PRNewswire/ -- Helixmith announced topline results today from a Phase 2A study in individuals with ALS (Amyotrophic Lateral Sclerosis). ALS is a fatal neurodegenerative disorder of upper and lower motor neurons that causes progressive paralysis and...Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19
KEY POINTS TADIOS was determined to be safe and well tolerated Serum levels of IL-1RA changed significantly, a biomarker that has a correlation with severity and mortality during COVID-19 infections Improvement in fatigue observed LA JOLLA, Calif., Aug. 3, 2022 Helixmith announced topline...Helixmith Announces VM202 (Engensis®) Presentation at New York Academy of Sciences "Advances in Pain" Meeting on May 3, 2022
Dr. Jack Kessler of Northwestern University will present "New Concept for Neuropathic Pain Relief with Regenerative Medicine Potential Based on Plasmid DNA Encoding Human Hepatocyte Growth Factor, VM202: Scientific Basis and Results from Clinical Studies" LA JOLLA, Calif., May 2, 2022...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Helixmith Co.
Sign Up For FreeTo access detailed company insights
Helixmith is a clinical-stage gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to address previously untreated diseases, and is listed on the KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector pr... Read More
